Source-grounded facts extracted from LEXICON PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
LEXICON PHARMACEUTICALS, INC. shareholders approved Election of Class II Directors at the 2023-04-27 meeting.
“Election of Class II Directors Name of Director For Withheld Broker Non-Votes Samuel L. Barker, Ph.D. 142,120,279 9,119,847 13,664,122 Christopher J. Sobecki 143,104,310 8,135,816 13,664,122 Judith L. Swain, M.D. 135,882,215 15,357,911 13,664,122”
LEXICON PHARMACEUTICALS, INC. reported the full-year ended December 31, 2022 results: net income Net loss of $101.9 million, or $0.62 per share, EPS $0.62 per share.
“Net loss for the full-year 2022 was $101.9 million, or $0.62 per share, as compared to a net loss of $87.8 million, or $0.60 per share in 2021.”
LEXICON PHARMACEUTICALS, INC. reported the three months ended December 31, 2022 results: net income Net loss of $30.5 million, or $0.16 per share, EPS $0.16 per share.
“Net loss for the fourth quarter of 2022 was $30.5 million, or $0.16 per share, as compared to a net loss of $25.6 million, or $0.17 per share, in the corresponding period in 2021.”
LEXICON PHARMACEUTICALS, INC. incurred credit facility of $25 million with Oxford Finance LLC.
“On December 30, 2022, we exercised our option to draw the second $25 million tranche under our loan and security agreement with Oxford Finance LLC (“Oxford”) and the second tranche was funded on such date .”
LEXICON PHARMACEUTICALS, INC. reported the three months ended September 30, 2022 results: net income $23.4 million, or $0.13 per share.
“Net loss for the third quarter of 2022 was $23.4 million, or $0.13 per share, as compared to a net loss of $23.1 million, or $0.16 per share, in the corresponding period in 2021.”
Jeffrey L. Wade was appointed as President at LEXICON PHARMACEUTICALS, INC..
“On September 3, 2021, in preparation for the potential commercial launch of sotagliflozin, if approved, and management of future growth of our company, our board of directors appointed Jeffrey L. Wade as president, effective October 1, 2021, continuing to report to Lonnel Coats, who remains our chief executive officer.”
Kristen L. Alexander was appointed as vice president of finance and accounting at LEXICON PHARMACEUTICALS, INC..
“Effective September 24, 2021, Kristen L. Alexander will become our vice president of finance and accounting and assume the function of our principal accounting officer.”
James F. Tessmer retired as vice president of finance and accounting at LEXICON PHARMACEUTICALS, INC..
“On July 28, 2021, James F. Tessmer notified us of his decision to retire as our vice president of finance and accounting, effective September 24, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.